Eric Lefkofksy's Bloomberg Interview Reveals Integrated Approach to Cancer Treatment

He created the technology company after discovering the technology available to physicians is not up to the standards of many industries. He recognized there was an opportunity to deliver personalized cancer care by integrating molecular data with clinical data. The data is then analyzed by AI and machine learning technology to provide physicians with the most up to date information on the particular patient. When he personally experienced the difficulty of a cancer diagnosis with a close family member, he recognized how confusing the whole industry was for patients.

 The patients simply didn’t have access to clear paths of what to do. He also revealed that it was shocking there was not more information and data available given the advances in technology in the last decade. He reveals that he recognized there was a large potential market by bringing in the technology to the medical industry that integrated information and could help physicians understand that information.

 It focuses on using genomic sequencing now that the price has dropped significantly to help physicians understand the cancer patient’s tumor at a molecular level. Lefkofsky indicates that this sequencing is different than the kind of sequencing companies like 23andMe do. Companies like 23andMe focus on disease prevention by helping people understand their genetic predisposition to specific diseases. The sequencing done at Tempus is focused on disease treatment. By using machine learning and AI, the company is able to provide predictive analysis of the best possible treatment plan available for each patient. The real-time solutions available to physicians through this technology allow physicians to provide individualized treatment plans for their patients.

believes the technology companies like Apple, Google, and Amazon making announcements about joining the health industry will ultimately be beneficial to the consumers. There are a few sections of the market that have not undergone a significant paradigm shift because of the revolutionized technology. However, with Apple, Google, and Amazon joining the market, technology will soon create a large impact on healthcare. He believes that technology should be used to help people live longer lives with a better quality of life.

 Eric Lefkofsky also believes that using AI and machine learning helps provide the company with a holistic overview of the entire patient. Combining the text, image, and molecular data is vital to understand the patient. Solving the cancer issue requires an integrated approach after witnessing the failure of other companies which only focus on one kind of data like clinical notes or sequencing. Instead, aims to look at every piece of medical data available on the patient to understand the best possible outcome.

 He also believes that this is simply a part of the growth of technology in the industry. Many companies that begin the paradigm shift in any industry are often not the most efficient. Instead, other companies build on the technology available to them. He uses the example of early search engines that did not have the ultimate impact that Google eventually would have. It has built on the technology available by scaling to larger data. They work with 250 hospital systems that funnel more than 25% of cancer patients. By gathering the information through so many different hospitals, they have created the largest library of molecular and clinical data.

 Eric Lefkofsky reveals that Groupon and the other entrepreneurial endeavors provided significant learning experiences for him. He builds on the information he gains in each experience by continuing what worked well and excluding what didn’t work.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.